TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07844967: A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07844967 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07844967 Rescue Dossier →